Fibroblast growth factor 21 – metabolic role in mice and men.
Endocr. Rev. 38, 468-488 (2017)
ince its identification in 2000, the interest of scientists in the hepatokine fibroblast growth factor (FGF) 21 has tremendously grown, and still remains high, due to a wealth of very robust data documenting this factor’s favorable effects on glucose and lipid metabolism in mice. For more than ten years now, intense in vivo and ex vivo experimentation addressed the physiological functions of FGF21 in humans as well as its pathophysiological role and pharmacological effects in human metabolic disease. This work produced a comprehensive collection of data revealing overlaps in FGF21 expression and function but also significant differences between mice and men that have to be considered before translation from bench to bedside can be successful. This review summarizes what is known about FGF21 in mice and humans with a special focus on this factor’s role in glucose and lipid metabolism and in metabolic diseases, such as obesity and type-2 diabetes mellitus. We highlight the discrepancies between mice and men and try to decipher their underlying reasons.
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Schlagwörter Nonalcoholic Fatty Liver; Serum Fgf21 Levels; Brown Adipose-tissue; Activated-receptor-gamma; Improves Insulin Sensitivity; Type-2 Diabetes-mellitus; Coronary-artery-disease; Beta-klotho Expression; Ppar-alpha Activation; Metabolic Syndrome
ISSN (print) / ISBN 0163-769X
Zeitschrift Endocrine Reviews
Quellenangaben Band: 38, Heft: 5, Seiten: 468-488
Verlag Oxford Univ Press Inc
Verlagsort Bethesda, Md.